Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real-World, retrospective clinical study to evaluate the safety and efficacy of Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL) by race and ethnicity

Next Previous
Trial Profile

A Real-World, retrospective clinical study to evaluate the safety and efficacy of Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL) by race and ethnicity

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 11 Dec 2022 According to a Kite Pharma media release, patients were treated across 78 U.S. authorized treatment centers.
  • 11 Dec 2022 Results (N=1383) published in a Kite Pharma media release.
  • 11 Dec 2022 According to a Kite Pharma media release, data from this study were presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top